12 To 15 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.5)
-
Publication number: 20130136742Abstract: Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.Type: ApplicationFiled: February 1, 2013Publication date: May 30, 2013Inventors: Kyunglim LEE, Youngjoo Kwon, Miyoung Kim, Moonhee Kim
-
Patent number: 8450273Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.Type: GrantFiled: April 9, 2008Date of Patent: May 28, 2013Assignees: The Board of Trustees of the University of Arkansas, Ochsner Clinic Foundation, National University Corporation Kagawa UniversityInventors: Joshua Sakon, Robert C. Gensure, Osamu Matsushita
-
Publication number: 20130130987Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.Type: ApplicationFiled: January 28, 2013Publication date: May 23, 2013Applicant: TRINITY THERAPEUTICS, INC.Inventor: Trinity Therapeutics, Inc.
-
Publication number: 20130130996Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.Type: ApplicationFiled: January 28, 2013Publication date: May 23, 2013Applicant: Biokine Therapeutics Ltd.Inventor: Biokine Therapeutics Ltd.
-
Publication number: 20130130978Abstract: Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.Type: ApplicationFiled: November 20, 2012Publication date: May 23, 2013Applicants: The Texas A&M University System, The Board of Regents, The University of Texas SystemInventors: The Board of Regents, The University of Texas, The Texas A&M University System
-
Publication number: 20130129715Abstract: Use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in therapeutic and contraceptive fields The present invention concerns the use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in tolerogenic or immunogenic form in the therapy for infertility or as contraceptive or post-coital interception means, respectively.Type: ApplicationFiled: July 13, 2011Publication date: May 23, 2013Inventors: Arcangelo Liso, Maria Matteo
-
Patent number: 8445448Abstract: The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.Type: GrantFiled: December 3, 2008Date of Patent: May 21, 2013Assignee: Apitope International NVInventor: David Wraith
-
Patent number: 8445443Abstract: The present invention discloses cell permeable p18 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a tumor suppressor p18. Also disclosed are polynucleotides encoding the cell permeable p18 recombinant proteins, an expression vector containing the cell permeable p18 recombinant protein, and a pharmaceutical composition for treating p18 deficiency or failure which contains the cell permeable p18 recombinant protein as an effective ingredient. The cell permeable p18 recombinant proteins of the present invention are capable of efficiently introducing a haploinsufficient tumor suppressor p18 into a cell, and thus, can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent.Type: GrantFiled: September 4, 2008Date of Patent: May 21, 2013Assignee: Procell Therapeutics Inc.Inventors: Daewoong Jo, Seolhwa Kim, Jung-Hee Lim, Kisuk Park, Se-Eun Kang
-
Patent number: 8445441Abstract: A purified polypeptide for inhibiting binding of BCL-2 to IP3 receptors includes an amino acid sequence consisting of about 10 to 80 amino acids. The amino acid sequence has a sequence identity at least 90% homologous to a portion of SEQ ID NO:1. The polypeptide inhibits binding of Bcl-2 to IP3 receptors of cells that express IP3R and Bcl-2 and induces apoptosis in a cell.Type: GrantFiled: August 26, 2011Date of Patent: May 21, 2013Assignee: Case Western Reserve UniversityInventors: Clark W. Distelhorst, Yiping Rong
-
Publication number: 20130123202Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: ApplicationFiled: December 4, 2012Publication date: May 16, 2013Applicant: MOREHOUSE SCHOOL OF MEDICINEInventor: Morehouse School Of Medicine
-
Patent number: 8440630Abstract: The present invention is to provide a polypeptide specifically inhibiting the activity of Akt (Protein Kinase B), the DNA thereof, the antibody thereof, an inhibitor of Akt activity or an antitumor agent, and the like. The polypeptide comprises polypeptides (SEQ ID NO: 1, 3, 5, 7, and 9 of the sequence listing) that contain an amino acid sequence corresponding to any of the position of amino acid residue 10-24 of human TCL1, amino acid residue 8-22 of human TCL1B, amino acid residue 5-19 of human MTCP1, and amino acid residue 9-24 of mouse or rat TCL1; and the derivatives. Further, the present invention includes DNA encording the polypeptide (SEQ ID NO: 2, 4, 6, 8 or 10 of the sequence listing), and the antibodies specifically binding to the polypeptides. The polypeptide of the present invention can be used for an inhibitor of Akt activity, an antitumor agent, or the like.Type: GrantFiled: December 14, 2004Date of Patent: May 14, 2013Assignee: Japan Science and Technology AgencyInventors: Masayuki Noguchi, Futoshi Okada, Makoto Hiromura
-
Patent number: 8440792Abstract: The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.Type: GrantFiled: October 25, 2010Date of Patent: May 14, 2013Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael R. Yeaman, Alexander J. Shen
-
Patent number: 8440793Abstract: Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (?-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the ?-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.Type: GrantFiled: March 20, 2009Date of Patent: May 14, 2013Assignee: Genzyme CorporationInventors: Michael A. Perricone, John Lyle Dzuris, Timothy E. Weeden, James E. Stefano, Clark Q. Pan, Andrea E. Edling
-
Patent number: 8440620Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.Type: GrantFiled: August 29, 2011Date of Patent: May 14, 2013Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Publication number: 20130115170Abstract: Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM 1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases.Type: ApplicationFiled: October 19, 2012Publication date: May 9, 2013Inventors: Robert Yu, Han-Chung Wu, Seigo Usuki
-
Patent number: 8435548Abstract: Disclosed are peptide derivatives, wherein glutathione-like peptides are connected to benzoic acid derivatives, and a cosmetic composition comprising the same. The peptide derivatives have excellent tyrosinase inhibition and anti-oxidative activities to show excellent skin whitening effect, biocompatibility without skin stimulation, and stability during long-term storage. Therefore, they can be effectively used for a cosmetic composition for skin whitening.Type: GrantFiled: December 23, 2009Date of Patent: May 7, 2013Assignee: Bio-FD&C Co., LtdInventors: Dai Hyun Jung, Sang Hyun Moh, Jung Hun Lee, Su Jung Kim, Hyung Sik Kim, Hyo Hyun Seo, Yeon Ja Bae
-
Publication number: 20130109619Abstract: A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.Type: ApplicationFiled: May 11, 2011Publication date: May 2, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya I. Tarasova, Giorgio Trinchieri, Howard A. Young, C. Andrew Stewart, Marco A. Cardone, Alan O. Perantoni
-
Patent number: 8431396Abstract: A purified polypeptide includes about 10 to about 40 amino acids and has an amino acid sequence corresponding to a portion of SEQ ID NO: 2. The polypeptide can inhibit binding of VEGF to VEGFR2 of cells that express VEGFR2.Type: GrantFiled: February 29, 2008Date of Patent: April 30, 2013Assignee: The Cleveland Clinic FoundationInventor: Bela Anand-Apte
-
Publication number: 20130102542Abstract: The invention is related to isoforms of components of transcription factor complexes that are specifically expressed in cancer cells. These isoforms can be used as biomarkers for detection, diagnosis, prognosis and monitoring of treatments of cancer, and as drug targets of pharmaceutical compositions for the treatment of various cancers expressing the targeted isoforms. Methods, molecules, materials and kits for these uses are disclosed.Type: ApplicationFiled: October 17, 2012Publication date: April 25, 2013Applicant: ONCOTX, INC.Inventor: Oncotx, Inc.
-
Publication number: 20130102522Abstract: Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to inhibit the activity of one or more protein kinases in vitro or in vivo. Also provided are methods of inhibiting a protein kinase in a subject by administration of an effective amount of a protein kinase inhibiting compound and the use of the protein kinase inhibiting compounds, alone or in combination with other chemotherapeutic agents, in the treatment of protein kinase mediated diseases and disorders.Type: ApplicationFiled: March 15, 2012Publication date: April 25, 2013Applicant: PHARMAGAP INC.Inventors: Raphael Terreux, Jenny Phipps
-
Patent number: 8426367Abstract: Provided herein are compositions and methods for binding outgrowth endothelial cells (OEC). The compositions consist of peptide ligands capable of binding OEC with high affinity and specificity. The compositions of the invention include peptides set forth in SEQ ID NO: 1-38 and variants and derivatives thereof. Compositions also include the nucleotide sequences encoding the peptides of the invention. The compositions find use in methods for the isolation of OEC and for the recruitment and retention of OEC to sites of therapeutic interest. Methods for the identification and isolation of other peptides capable of binding OEC are also provided.Type: GrantFiled: March 5, 2008Date of Patent: April 23, 2013Assignees: The University of North Carolina at Chapel Hill, North Carolina State University, The Ohio State University Research FoundationInventors: Cam Patterson, Anka Veleva, Stuart Cooper
-
Publication number: 20130096072Abstract: Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.Type: ApplicationFiled: October 12, 2012Publication date: April 18, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Patent number: 8415292Abstract: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface.Type: GrantFiled: October 20, 2009Date of Patent: April 9, 2013Assignee: Trustees of Dartmouth CollegeInventors: Dean Madden, Patrick R. Cushing, Prisca Boinguérin, Rudolf Volkmer, Lars Vouilleme
-
Patent number: 8415306Abstract: The present invention relates to insulin-like growth factor 1 receptor binding peptides, polynucleotides encoding them, and methods of making and using the foregoing.Type: GrantFiled: May 25, 2011Date of Patent: April 9, 2013Assignee: Janssen Biotech, Inc.Inventors: Michael Diem, Karyn O'Neil
-
Publication number: 20130085107Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.Type: ApplicationFiled: November 9, 2010Publication date: April 4, 2013Applicant: IRONWOOD PHARMACEUTICALS, INCInventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer
-
Patent number: 8410059Abstract: Therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt are described. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: GrantFiled: July 8, 2011Date of Patent: April 2, 2013Assignee: Biokine Therapeutics Ltd.Inventors: Nobutaka Fujii, Hirokazu Tamamura, Akira Hori
-
Patent number: 8409584Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.Type: GrantFiled: May 5, 2010Date of Patent: April 2, 2013Assignee: New York UniversityInventors: Thomas M. Wisniewski, Fernando Goni
-
Publication number: 20130079287Abstract: Provided is a caffeoylalphaneoendrophin peptide derivative, and use thereof, as an anti-itching agent and an anti-atopic agent. More specifically, provided is a caffeoyl endorphin peptide derivative, which is applicable in a cosmetic material for anti-inflammatory use, such as for an atopic dermatitis treatment, and the like. The caffeoyl endorphin peptide derivative is safe for skin, has resistance to degradation by peptidases, and the like, and also has an excellent stability with respect to temperature change, and the like.Type: ApplicationFiled: December 29, 2011Publication date: March 28, 2013Inventors: Dai Hyun JUNG, Sang Hyun Moh, Jeong Hun Lee, Su Jung Kim, Hyo Hyun Seo, Chang II Lim, Ji Yeon Sung, Ae Jin Jeong
-
Patent number: 8404646Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: GrantFiled: September 28, 2011Date of Patent: March 26, 2013Assignees: Cornell Research Foundation, Inc., Institut de Recherches Cliniques de MontrealInventors: Peter W. Schiller, Hazel H. Szeto, Kesheng Zhao
-
Patent number: 8404647Abstract: The invention relates to PAD inhibitors that are suitable to be used as a medicament against an autoimmune disease such as RA.Type: GrantFiled: December 10, 2010Date of Patent: March 26, 2013Assignees: Chiralix B.V., Modiquest B.V., Academisch Ziekenhuis Leiden H.O.D.N. LumcInventors: Richard Hendrik Blaauw, Gerardus Jozef Maria Pruijn, Jozef Maria Hendrik Raats, Floris Petrus Johannes Theodorus Rutjes, Jan Wouter Drijfhout
-
Publication number: 20130072425Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.Type: ApplicationFiled: December 17, 2010Publication date: March 21, 2013Applicant: Children's Medical Center CorporationInventor: Randolph Watnick
-
Publication number: 20130072447Abstract: The invention is directed to pharmaceutical compositions and methods for delivery of a therapeutic or diagnostic agent from one bodily compartment to one or more other bodily compartment by administering one of the following conjugates: a polymer having multiple functional groups at least one of which is covalently bound to a therapeutic or diagnostic agent, and at least one cell uptake promoter covalently bound to the therapeutic or diagnostic agent; or a polymer and at least one cell uptake promoter bound thereto; the polymer further comprising multiple functional groups at least one of which is covalently bound a therapeutic or diagnostic agent.Type: ApplicationFiled: May 14, 2012Publication date: March 21, 2013Applicant: Rutgers, The State University of New JerseyInventors: Srinivasan Ramanathan, Stanley Stein, Michael Leibowitz, Patrick J. Sinko, Tamara Minko, Gregory C. Williams, Goubao Zhang, Xiaoping Zhang, Shahrair Pooyan, Seong Hee Park, Bo Qiu, Pankaj Paranjpe
-
Publication number: 20130064790Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: ApplicationFiled: March 8, 2012Publication date: March 14, 2013Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Lorea MANTEROLA CAREAGA, Inés Noelia CASARES LAGAR, Nancy Díaz-Valdés Farray, Javier DOTOR DE LAS HERRERÍAS, Juan José LASARTE SAGASTIBELZA, Pablo SAROBE UGARRIZA, Jesús PRIETO VALTUEÑA, Francisco BORRÁS CUESTA
-
Patent number: 8394758Abstract: Tumor targeting peptides and uses thereof in tumor diagnosis and treatment.Type: GrantFiled: October 28, 2009Date of Patent: March 12, 2013Assignee: Academia SinicaInventors: Han-Chung Wu, De-Kuan Chang, Chien-Yu Chiu
-
Publication number: 20130058991Abstract: Chemoattractant polypeptide compounds for progenitor cells and compositions and drug products comprising the compounds are provided herein. Methods for attracting progenitor cells to a location in or on a patient also are provided along with methods of growing and repairing bone.Type: ApplicationFiled: October 8, 2010Publication date: March 7, 2013Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Vineet Agrawal, Stephen F. Badylak, Scott Alan Johnson, Stephen Tottey
-
Publication number: 20130059773Abstract: The present invention concerns compounds modulating apoptosis of neutrophil cells. In particular, the invention concerns compounds inhibiting an interaction between Proliferating Cell Nuclear Antigen (PCNA) and proteins binding to cytoplasmic PCNA in neutrophil cells, for use in the treatment of a disease involving a neutrophil-dependent inflammatory process. The invention also relates to a method for the identification of a compound for use in the treatment of a neutrophil-dependent inflammatory process. The invention further relates to peptides for use in the treatment of neutropenia.Type: ApplicationFiled: February 24, 2011Publication date: March 7, 2013Inventor: Veronique Witko-Sarsat
-
Patent number: 8389481Abstract: Disclosed herein are novel glutamate-enhanced cell-penetrating peptides (CPPs) for use as delivery vehicles to mediate intracellular uptake of therapeutic payloads and methods of using the same.Type: GrantFiled: November 12, 2009Date of Patent: March 5, 2013Assignee: University of Medicine and Dentistry of New JerseyInventors: Beverly E. Barton, H. Dan Lewis, Robert J. Donnelly, Ali Husain, Dimitrios Barlos, Sheraz Riaz
-
Publication number: 20130053324Abstract: There is described a group of novel self-assembling peptides (SAPs), comprising biotinylated and unbiotinylated sequences, hybrid peptide-peptoid sequences, branched sequences for a total of 48 tested motifs, showing a heterogeneous ensemble of spontaneously self-assembled structures at the nano- and microscale, ranging from short tabular fibers to twisted ribbons, nanotubes and hierarchical self-assembled micrometer-long sheets. Specifically, the SAPs according to the present invention which initially spontaneous assemble, surprisingly form stable solid scaffolds upon exposure to neutral pH buffer. Further these SAPs allow adhesion, proliferation and differentiation of murine and human neural stem cells and have self-healing propensity. They also did not exert toxic effects in the central nervous system, can stop bleeding and foster nervous regeneration.Type: ApplicationFiled: April 19, 2011Publication date: February 28, 2013Applicant: UNIVERSITA' DEGLI STUDI DI MILANO BICOCCAInventors: Angelo Luigi Vescovi, Fabrizio Gelain
-
Publication number: 20130053321Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.Type: ApplicationFiled: May 14, 2012Publication date: February 28, 2013Inventors: Daria Mochly-Rosen, Xin Qi, Nir Qvit
-
Publication number: 20130053330Abstract: The outcome of an in vitro fertilization (IVF) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (HRG) gene or protein analysis of HRG. The proline isoform of HRG or an amino acid fragment thereof can further be used to increases the success of pregnancy of a woman.Type: ApplicationFiled: March 30, 2011Publication date: February 28, 2013Applicant: Karolinska Institutet Innovations ABInventors: Karin Karehed, Helena Akerud
-
Publication number: 20130045928Abstract: Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, for the prophylaxis or treatment of airway diseases, including but not limited to inflammation-related airway diseases, acute asthma or COPD, methods of prophylaxis and treatment of airway diseases and pharmaceutical compositions and formulations for the prophylaxis or treatment of airway diseases.Type: ApplicationFiled: October 17, 2012Publication date: February 21, 2013Applicant: PALATIN TECHNOLOGIES, INC.Inventor: PALATIN TECHNOLOGIES, INC.
-
Publication number: 20130045922Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof.Type: ApplicationFiled: January 27, 2011Publication date: February 21, 2013Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Avner Adini, Robert D'Amato
-
Publication number: 20130045239Abstract: A method of modulating the pharmacodynamic effect of a GC-C receptor agonist polypeptide formulation in a subject in need of such treatment is disclosed, The method comprises administering the GC-C receptor agonist polypeptide formulation to the subject before the ingestion of food.Type: ApplicationFiled: August 13, 2010Publication date: February 21, 2013Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Jeffrey Johnston, Caroline Kurtz
-
Patent number: 8377885Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.Type: GrantFiled: February 29, 2012Date of Patent: February 19, 2013Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Shai Rubnov
-
Patent number: 8378072Abstract: The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the modulation of unwanted immune responses, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use.Type: GrantFiled: April 13, 2007Date of Patent: February 19, 2013Assignee: Declion Pharmaceuticals, Inc.Inventor: Dustan Bonnin
-
Patent number: 8377883Abstract: The present invention relates to a peptide for anti-angiogenesis and use thereof, in particular, to a peptide useful for treating angiogenesis diseases; a polynucleotide coding the peptide; a vector and a cell comprising the polynucleotide; a pharmaceutical composition comprising the peptide, the fused peptide or the fused protein, the polynucleotide, the vector and/or the cell. The peptide, the fused peptide or the fused protein, the polynucleotide, the vector, the cell and/or the pharmaceutical composition can be used for treatment of associated diseases such as tumor by anti-angiogenesis.Type: GrantFiled: September 29, 2007Date of Patent: February 19, 2013Assignee: Beijing Institute for Cancer ResearchInventors: Chengchao Shou, Yahui Su, Qin Feng
-
Patent number: 8377890Abstract: A hair treatment agent having advantageous properties is provided. The hair treatment agent contains, based on weight of the agent, 0.00001 to <0.05% by weight of at least one oligopeptide having at least one amino acid sequence Glu-Glu-Glu (formula (A)), wherein the amino group may be present in a free or protonated manner, and the carboxy groups may be present in a free or deprotonated manner.Type: GrantFiled: March 3, 2011Date of Patent: February 19, 2013Assignee: Henkel AG & Co. KGaAInventors: Erik Schulze Zur Wiesche, Petra Westphal, Elisabeth Poppe
-
Publication number: 20130039939Abstract: The present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates. In particular, the present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates comprising a lipid-containing moiety representing an adjuvant moiety, a peptide or protein moiety whereby said peptide or protein moiety represents at least one antigenic structure, the antigen-moiety, and, optionally, a conjugate moiety, preferably a monodisperse polyethyleneglycol unit. Said compounds are particularly useful for therapeutic or prophylactic vaccination by mucosal or systemic administration, preferably mucosal and systemic vaccination. That is, the present invention relates in another aspect to pharmaceutical compositions comprising the compounds according to the present invention, in particular, said pharmaceutical compositions are vaccines.Type: ApplicationFiled: December 12, 2009Publication date: February 14, 2013Inventors: Thomas Ebensen, Carlos Alberto Guzman, Michael Morr, Werner Tegge
-
Publication number: 20130040886Abstract: The present invention comprises peptide compositions and methods for specifically inhibiting signaling through G? subunits.Type: ApplicationFiled: March 21, 2012Publication date: February 14, 2013Applicant: The Board of Trustees of the University of IllinoisInventors: Guy LeBreton, Jin-Sheng Huang, Subhashini Srinivasan, Fadi T. Khasawneh
-
Patent number: RE44022Abstract: The invention relates to cyclopeptides, the method of their preparation and their utilization as inhibitors or activators of angiogenesis. These cyclopeptides comprise contain the following peptide sequence: -Arg-Ile-Lys-Pro-His-Gln-Gly- ??(SEQ ID NO: 1). They can be used in systems for inhibition of angiogenesis that comprises include a support (1), to which the cyclopeptide is affixed by means of coupled via an organic spacer arm (3) that may be provided with a moiety (4) capable of being spliced cleaved by an enzyme system.Type: GrantFiled: October 2, 2001Date of Patent: February 19, 2013Assignees: Commissariat a l'Energie Atomique, Universite Victor Sagalen Bordeaux 2, Universite de Bordeaux 1Inventors: Andreas Bikfalvi, Juliette Boulard, Antonin Boulard, Liliane Dequaire, Romane Boulard, Sara Boulard, Julie Deleris, Christiane Deleris, Marie Deleris